

COMPANY REGISTRATION NUMBER : 7225131

**BASO ~ THE ASSOCIATION FOR CANCER SURGERY  
COMPANY LIMITED BY GUARANTEE  
UNAUDITED FINANCIAL STATEMENTS  
FOR  
YEAR ENDED 30 JUNE 2025**

**Charity Number : 1136067**



Edmund Carr LLP  
Chartered Accountants  
146 New London Road  
Chelmsford  
Essex  
CM2 OAW

**BASO - THE ASSOCIATION FOR CANCER SURGERY  
COMPANY LIMITED BY GUARANTEE  
FINANCIAL STATEMENTS**

**YEAR ENDED 30 JUNE 2025**

---

<b>CONTENTS</b>	<b>PAGE</b>
Company information	<b>1</b>
Trustees' annual report	<b>2</b>
Independent Examiner's report to the Trustees	<b>12</b>
Statement of financial activities	<b>13</b>
Balance sheet	<b>14</b>
Notes to the financial statements	<b>15</b>

**BASO - THE ASSOCIATION FOR CANCER SURGERY  
COMPANY LIMITED BY GUARANTEE**  
**COMPANY INFORMATION**

**YEAR ENDED 30 JUNE 2025**

---

**Charity Number** 1136067

**Company Number** 7225131

**Registered Office** 38-43 Lincoln's Inn Fields  
London  
WC2A 3PE

**THE TRUSTEES**

The Trustees of the charity are also the directors of the charity.

The Trustees who served the charity during the year were as follows:

Professor Michael Douek	President
Professor Jayant Vaidya	Vice President
Professor Anant Desai	Honorary Secretary
Mr Michael Shackcloth	Honorary Treasurer (Demitted 4/11/2024)
Miss Abigail Tomlins	Honorary Treasurer (Appointed 4/11/2024)
Mr John Whiting	EJSO Representative (Demitted 4/11/2024)
Professor PG Roy	EJSO Representative (Appointed 4/11/2024)
Professor Jim Khan	Meeting Secretary
Mr Avi Agrawal	
Miss Melissa Cunha	Deputy Meeting Secretary
Mr Aaron Quyn	
Mr Paul Skaife	
Professor Anastasios Kanatas	(Appointed 4/11/2024)
Ms Gloria Petralia	(Appointed 4/11/2024)
Mr Ibrahim Sallam	(Appointed 4/11/2024)

**BASO - THE ASSOCIATION FOR CANCER SURGERY  
COMPANY LIMITED BY GUARANTEE  
TRUSTEES' ANNUAL REPORT  
YEAR ENDED 30 JUNE 2025**

---

The Trustees have pleasure in presenting their report and the unaudited financial statements for the charity for the year ended 30th June 2025. The Trustees of the charity as shown above are also the directors of the charity.

**OBJECTIVES AND ACTIVITIES**

The Charity's objectives are:

**To advance the science, practice, and art of surgical oncology** for the benefit of patients with cancer; and **to promote research, training, and education in surgical oncology** for the benefit of the public, patients and the medical community, and to disseminate the useful results of that research appropriately.

The Association serves as an umbrella organisation for professionals across all surgical cancer specialties and cancer research. Additionally, the Society is dedicated to driving innovation in cancer care, supporting the training and development of the future workforce, and ensuring our activities align with the Charity Commission's guidance on public benefit.

**Portfolio of BASO Prizes and Awards**

The Association is proud to offer a variety of awards aimed at inspiring our junior colleagues and fostering their passion for surgical oncology, cancer research, and patient care. For more details, visit: <https://baso.org.uk/education-training.aspx>. At our annual scientific meeting, the Society continues to present the following prestigious prizes:

- **Alan Edwards Memorial Prize** is awarded to the best poster presentation.
- **Ronald Raven Presentation Prize** is awarded to the best oral paper presentation.
- **BASO~ACS Presentation Prize**, formerly known as BJS Prize, is awarded to the best oral paper presentation. As a result of a structural change, the British Journal of Surgery Society (BJSS) ceased its support for this prize. In 2019, BASO Council unanimously decided to sponsor this prize to ensure continued existence to the BJS Paper Presentation Prize awarded at the BASO Meeting.
- **BASO Trainees (poster/oral presentation) Prize** is awarded to the best poster and oral paper presentations at the BASO Trainees Meeting.

To expand its commitment to all cancer-related professionals, BASO also presents the following prizes:

- **BASO Trainees Audit/QIP Prize** to support and encourage trainees, those involved with audit and quality improvement with a view of improving care to patients, in particular, cancer patients.
- **BASO Multidisciplinary Prize** to recognise the work done by our Non-Medical Professional colleagues in supporting cancer patients. This unique award is designed to highlight any research, audit, quality improvement, health service provision/development, cancer patient pathway study, cancer survivorship study.
- **BASO Medical Student Prize** to support and encourage medical students with an interest in surgical oncology.

**BASO - THE ASSOCIATION FOR CANCER SURGERY  
COMPANY LIMITED BY GUARANTEE  
TRUSTEES' ANNUAL REPORT (continued)**

**YEAR ENDED 30 JUNE 2025**

---

Additionally, BASO annually offers a range of prizes to encourage and promote trainees' enthusiasm for surgical oncology. These awards are presented to the trainee who delivers the best surgical oncology presentation at various surgical specialty associations' annual scientific conferences.

BASO has established a prestigious collection of awards, recognising surgeons for their outstanding achievements and contributions to cancer surgery, research, and education.

In addition to the **Ronald Raven Lifetime Achievement Award** (introduced in 2013), the **Geoff Oates Award** (2014), and the **Uccio Querci della Rovere Award** (2014), BASO introduced the **BASO Medal for Excellence** in 2022 to mark the 50th anniversary of the Association's founding. This prestigious honour recognises outstanding contributions by individual surgeons or teams in advancing cancer care through excellence in **research, clinical practice, education, and innovation**.

The **BASO Medal for Excellence** is an international accolade presented every five years, with nominations open to both members and non-members. It recognises outstanding contributions to the advancement of cancer surgery in the UK. BASO was proud to award the **inaugural medal to Professor Freddie Hamdy** in July 2022.

For more details, follow the link: <https://baso.org.uk/baso~acs-conferences/baso-50thanniversary-meeting.aspx>

**BASO~ACS Research Grants**

BASO continues to expand its portfolio of research grants to support innovative cancer research. For more information, visit: <https://baso.org.uk/education-training.aspx>

**Ronald Raven Travelling Fellowship**

Established in 1993 by the Ronald Raven Trustees in memory of Ronald W. Raven, the founder of the Association, this fellowship is awarded annually. BASO continues to fund this **£3,000 fellowship**, supporting aspiring trainees in developing their skills and experience in surgical cancer treatment.

**BASO (NIHR) Research Project Grant**

As a non-commercial partner with the National Institute for Health Research (NIHR), BASO successfully ran a research project grant scheme to assist surgeons undertaking cancer-related research. Awarded projects were eligible for Clinical Research Network Support and inclusion in the NIHR portfolio.

In 2021, BASO launched a new **Research Grant in Cancer Surgery** in collaboration with the **Rosetrees Trust**, which replaced the BASO (NIHR) Research Project Grants in 2022.

**BASO/Rosetrees Research Grants in Cancer Surgery**

To celebrate BASO's 50th Anniversary, the National Committee introduced a new three-year research grant partnership with the Rosetrees Trust. This collaboration provides **annual grants of up to £50,000**, with matching funds from the Rosetrees Trust.

The first round of grants was awarded at BASO's 50th Anniversary Celebration Meeting. Successful applications may be considered for inclusion in the **NIHR portfolio** and are encouraged to seek support from the **Royal College of Surgeons of England's Surgical Interventional Trials Unit (SITU)**.

**BASO - THE ASSOCIATION FOR CANCER SURGERY  
COMPANY LIMITED BY GUARANTEE  
TRUSTEES' ANNUAL REPORT (continued)**

**YEAR ENDED 30 JUNE 2025**

---

***Endorsement of Regional Events***

The Association strives to engage with oncologists and related societies at the regional level. Through its network of Regional Representatives, BASO has actively supported a variety of regional and national meetings throughout this accounting year.

***Engagement with Medical Students***

In its commitment to nurturing the next generation of surgical oncologists, the Association has opened its Trainee membership to Foundation Year Trainees and Medical Students aspiring to pursue a career in surgical oncology. BASO provides valuable support for their surgical career development through skills courses, mentoring sessions, and portfolio guidance, leveraging its extensive network of regional representatives.

The Society also actively engages with undergraduate Medical Societies by sponsoring annual meetings with the BASO Prize and hosting sponsored lectures.

***BASO Trainees Group***

The BASO Trainees group has consistently broadened its reach and strengthened ties with trainee groups across the UK and Europe. These collaborations have allowed us to inspire trainees in the principles of research and clinical excellence in surgical oncology, through the sponsorship of prizes and lectures at national specialty meetings. Our Trainees group remains committed to advancing research, academic training, education and fellowship opportunities.

***BASO's contribution to NICE consultations***

The Society continues to make a significant impact by providing expert advice on numerous site-specific surgical cancer consultations and guidelines, as requested by NICE. Our Council members actively contribute to various Cancer Clinical Reference Groups (CRGs), offering their specialised expertise.

Additionally, the Society maintains strong relationships with surgical societies and the Royal Colleges, while continuously seeking new opportunities for collaboration.

**ACHIEVEMENTS AND PERFORMANCE**

The Society remains firmly committed to supporting the training and educational development of its members and colleagues. It continues to demonstrate the value of a unified umbrella organisation by **actively growing its membership, fostering research collaborations through grant funding, and supporting a wide range of educational events**. Backed by **sound financial stability**, the Society is well positioned to **deliver high-quality educational meetings and initiatives that advance cancer surgery and cancer research**.

***BASO Annual Scientific Meeting***

**BASO 2024** delivered an exceptional programme, featuring a distinguished lineup of national and international experts in cancer surgery. Themed “**Surgical Excellence in Cancer Care**,” the meeting was led by BASO President Professor Michael Douek, Meeting Secretary Professor Jim Khan, and Deputy Meeting Secretary Miss Melissa Cunha, and offered a rich mix of educational and thought-provoking sessions across all aspects of surgical oncology.

The conference featured plenary sessions, keynote lectures, and roundtable discussions spanning a wide range of disciplines, fostering collaboration, networking, and the exchange of ideas among professionals.

**BASO - THE ASSOCIATION FOR CANCER SURGERY  
COMPANY LIMITED BY GUARANTEE  
TRUSTEES' ANNUAL REPORT (continued)  
YEAR ENDED 30 JUNE 2025**

---

**To enhance member benefits and encourage participation**, registration fees were **subsidised for BASO and Trainee members**, improving accessibility for our valued community.

The meeting focused on best practices in surgical oncology, delivering valuable insights into surgical cancer research and management across various specialties. It provided excellent learning opportunities for both experienced consultants and trainees—whether pursuing a career in surgical oncology or exploring other surgical disciplines. Delegate feedback was overwhelmingly positive.

Approximately 100 abstracts were submitted, with eight abstract prizes awarded for outstanding presentations. The programme also included several prestigious eponymous lifetime achievement awards and orations, honouring some of the leading surgeons of our time.

BASO remains committed to building on the success of this programme while ensuring the financial sustainability of future BASO meetings.

**European Journal of Surgical Oncology**

The **EJSO**, co-owned by BASO and ESSO, continues to thrive with improved submission quality and increased article downloads. The 2024 impact factor, released in June, has risen to 4.424 (for more details, visit: [https://journalinsights.elsevier.com/journals/0748-7983/impact\\_factor\\_5\\_year](https://journalinsights.elsevier.com/journals/0748-7983/impact_factor_5_year)). This significant increase in citations is a testament to the outstanding work of the editorial team, led by our past President, Professor Riccardo Audisio (Editor-in-Chief).

**Network and links with other organisations**

The Association is actively building and strengthening links with other specialties, fostering collaboration through membership partnerships, advisory input, mentoring opportunities, and plans for future joint conferences.

To further encourage collaboration and engagement, BASO Trainees is actively working with various trainees groups as well medical student societies to inspire and support medical students interested in careers in surgical oncology.

**European Society of Surgical Oncology**

BASO maintains a strong partnership with its European sister society, **ESSO**. Under their Memorandum of Understanding, BASO members enjoy full ESSO membership privileges, including reduced registration for conferences and courses, access to career development programs, members-only website content, and voting rights at the ESSO General Assembly.

**National Clinical Guidelines**

BASO plays a key role in developing and updating National Clinical Guidelines. Council members serve as Specialist Advisors for NICE's Interventional Procedure Programmes, while BASO Trustees actively contribute to consultations and participate in multiple Cancer Commissioning Groups.

**All-Party Parliamentary Group on Cancer**

BASO is a stakeholder in the All-Party Parliamentary Group on Cancer. As the sole organisation representing the surgical community, BASO is uniquely positioned to engage policymakers and advocate for the interests of oncology surgeons.

**BASO - THE ASSOCIATION FOR CANCER SURGERY  
COMPANY LIMITED BY GUARANTEE  
TRUSTEES' ANNUAL REPORT (continued)**

**YEAR ENDED 30 JUNE 2025**

---

**Cancer Services Committee**

BASO has chaired the Royal College of Surgeons of England's Cancer Services Committee (CSC) over 20 years, which united representatives from all surgical societies, Royal Colleges, patient liaison groups, and Macmillan to present a unified surgical voice on cancer care.

Paused in May 2022 to review its remit and structure, the CSC was reinstated following BASO's discussions with the College and continued to play a key role in shaping cancer service policy and commissioning.

In January 2025, the RCS announced a restructure of all its committees, including the CSC. The restructured CSC would sit under the Workforce and Planning Group, to be chaired and co-chaired by RCS Council members, with full administrative support from the College. BASO awaits further updates on this transition.

**National Committee for Cancer Surgery**

The BASO~ACS Council is proud to announce the establishment of a new and independent **National Committee on Cancer Surgery (NCCS)**, which aspires to be the *one unified voice* for cancer surgery in the UK. The NCCS serves as a critical and independent authority on policy and strategy (including infrastructure), answerable solely to patients and cancer surgeons. Its primary remit is to drive the delivery of the highest quality cancer treatment, alongside providing strategic advice on research and development, and fostering engagement with international and global cancer surgery communities.

To ensure it truly represents the voice of cancer surgery, the NCCS includes representation from all major surgical societies, the four Royal Colleges of Surgeons, the Royal College of Pathologists, the Royal College of Radiologists, and the Royal College of Obstetricians and Gynaecologists. The committee provides independent, expert advice to the NHS, the Department of Health (DoH), and the All-Party Parliamentary Group for Cancer (APPGC). It also produces and publishes policy documents and works to disseminate these widely through leading medical journals, the public, press, and policymakers.

In 2025, the NCCS successfully convened three committees and has set ambitious plans to continue and expand its work into 2026.

**BASO/Rosetrees Research Grants in Cancer Surgery**

In recognition of the success of this partnership, the **Rosetrees Trust** has agreed to **extend the collaboration for a further five years under the same funding arrangement**, allowing BASO~ACS to continue awarding these research grants. BASO Council is thankful to the Rosetrees Trust for their support in reaching this milestone.

**Sponsorship Platform for Clinical Trials**

BASO Council has developed a sponsorship platform and has secured the necessary contractual, legal, and insurance expertise to enable BASO~ACS to sponsor clinical trials that are considered important and worthy of support by the Society. This function is currently managed by NHS Trusts or universities.

**BASO - THE ASSOCIATION FOR CANCER SURGERY  
COMPANY LIMITED BY GUARANTEE  
TRUSTEES' ANNUAL REPORT (continued)  
YEAR ENDED 30 JUNE 2025**

---

**Covid Inquiry Submission**

BASO~ACS submitted a witness statement to the **COVID-19 Inquiry**, presenting the Society's perspective on events during the pandemic. The statement was prepared in the format requested by the Inquiry team, and BASO has been informed that **no in-person attendance will be required**.

**Medical Student Elective Award**

BASO Council has approved the establishment of a bursary to support medical students undertaking an elective in surgical oncology. The award will provide up to £2,000 to one or two successful applicants. The call for applications will be announced shortly, offering travel support for medical students during their surgical oncology electives over the coming year.

**BASO Endorsed Meetings**

This year, BASO endorsed the following events and meetings:

- International Masterclass in Hepatobiliary Surgery – September 2023
- Effective Tumour Board Setup and Multidisciplinary Decision making For Cancer Patients – December 2024
- 9<sup>th</sup> Portsmouth Colorectal Congress – June 2025
- BASO @BGCS Annual Conference - July 2025

BASO~ACS remains committed to advancing cancer treatment, research, patient care, and the education and training of the next generation of oncologists.

**FINANCIAL REVIEW**

**Membership**

Membership numbers have remained steady over the past year. The Society recognises the importance of growing its membership base and will be placing renewed emphasis on targeted recruitment and engagement initiatives in the coming year.

To support this objective and to encourage new members to join, the **membership fees will remain unchanged for this accounting period**. This approach aims to maintain accessibility while the Society works to expand its reach and strengthen its professional community.

As agreed at the 2017 AGM, BASO offers a 50% discount on Full Membership for a period of two years to BASO Trainees members who have completed their training. This benefit is available to those who have maintained continuous membership for two consecutive years as paying members.

**EJSO**

Profits generated from the *EJSO* continue to play an important role in supporting the Society. These profits are used to offset the cost of membership subscriptions to the journal and are reflected in the Society's final financial reconciliation.

In 2024, the journal delivered a **healthy profit of £113,512** to BASO~ACS, after deducting the Society's membership subscription costs for the year. This strong financial performance highlights the journal's ongoing value as both a scientific resource and a revenue stream.

**BASO - THE ASSOCIATION FOR CANCER SURGERY  
COMPANY LIMITED BY GUARANTEE  
TRUSTEES' ANNUAL REPORT (continued)**

**YEAR ENDED 30 JUNE 2025**

---

Revenue from **electronic institutional subscriptions**—primarily through e-only licences and bundled collections—has continued to show **steady growth**, reflecting the wider shift toward digital access. Conversely, and as expected, **print subscription revenues have declined** as more institutions and individuals transition to online formats.

There has also been a **notable increase in the number of authors choosing to publish Open Access**. This trend has generated **substantial growth in Open Access revenue**, supported by the journal's global reach and impact. BASO members continue to benefit from a **30% discount on Open Access publication fees**, which supports and encourages member-led research dissemination.

Looking ahead, it is anticipated that the *EJSO* will continue its positive trajectory and expand its impact under the **editorship of Professor Riccardo A. Audisio**.

**BASO Grants and Prizes**

**1. BASO/Rosetrees Research Grants in Cancer Surgery** 2024 is awarded to:

Mr George Adigbli - *Lymph Liquid Biopsy for Early Melanoma Risk Stratification: A Proof-of-Concept Study*

Dr Jack Helliwell - *Determining the role of the microbiome in the development of anaStomotic leak after rectal cancer surgery: a proSpectiVE obseRvational study (DISCOVERY)*

Miss Mhairi Mactier - *Exploring the association between post-operative complications and oncological outcomes in breast cancer surgery*

**2. Ronald Raven Travelling Fellowship Grant** 2024 is awarded to **Ms Andrea Sheel**, HPB and General Surgeon, University of Liverpool NHS FT.

**3. BASO Trainees Prize** were awarded at the following external meetings:

SCTS Annual Scientific Meeting

ASiT Annual Conference

BASO Trainees Research Forum

**BASO Annual Meeting 2024**

The BASO Trustees remain confident that the Charity is successfully fulfilling its objectives by promoting and supporting advancements in surgical oncology research and education. This commitment was clearly reflected in the success of the **2024 Annual Scientific Meeting**.

While the event incurred a **planned loss** due to the higher logistical costs of hosting in London, this outcome had been anticipated and strategically approved by the National Committee. The decision to offer **subsidised registration for junior members** was made to support early-career professionals and encourage greater engagement with the Society. The Committee agreed that delivering a high-quality, well-attended meeting was essential to advancing BASO's charitable aims and would also contribute to **long-term membership growth**.

The conference significantly **enhanced the Association's profile within the cancer research community**, strengthened collaborations with partner organisations, and provided an **outstanding networking platform** for BASO members. These efforts have already resulted in the **recruitment of new members** and increased visibility of the Society's work.

---

**BASO - THE ASSOCIATION FOR CANCER SURGERY  
COMPANY LIMITED BY GUARANTEE  
TRUSTEES' ANNUAL REPORT (continued)**

**YEAR ENDED 30 JUNE 2025**

---

BASO continues to maintain **strong financial reserves** and has secured a **sustainable income stream from the EJSO**, which will support ongoing investment in education, training, and research through future Annual Conferences. Looking ahead, the Trustees are committed to **transitioning towards a cost-neutral conference model**, while maintaining the high standards and impact of BASO events.

**Reserves Policy**

BASO~ACS maintains a prudent level of reserves to ensure the Association can meet its financial obligations in the event of a shortfall from the annual conference, while also supporting low delegate fees and avoiding increases to Membership fees. The level of reserves, together with income from conferences and subscriptions, remains central to achieving the Association's objectives.

The Trustees carefully monitor reserves to maintain an appropriate balance between safeguarding financial stability and keeping costs for Members and prospective Members as low as possible. They consider it prudent to hold free reserves in the region of £125,000 to cover the costs of the annual scientific conference, annual administration, and commitments made towards BASO/Rosetrees Research grants.

As at 31 March 2025, free reserves stood at £218,595, exceeding the target threshold. This strong position enables BASO~ACS to continue its policy of maintaining low subscription fees, subsidising conference registration fees for delegates, supporting further research grants. The reserve also provide a safeguard against any unforeseen operational costs of the BASO Office.

**Investment Policy**

The Trustees have power under the Articles to invest funds in the same manner and subject to the same conditions as the Trustees of a trust are permitted to do by the Trustee Act 2000. The Association currently holds its reserves across three deposit accounts: BASO ~ ACS holds reserves in a Scottish Widows 90-day notice account; an instant access account with Lloyds TSB; and a further instant access account with Virgin Money. BASO Trustees are looking into new investment opportunities for the Association's reserves.

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Structure**

On 1st July 2010, a formal transfer was made from the unincorporated charity, *BASO ~ The Association for Cancer Surgery*, to a newly incorporated company limited by guarantee of the same name (Company No. 7225131, Registered Charity No. 1136067). The company had been incorporated on 15 April 2010, when new Articles of Association were established.

At the same time, corresponding transfers were made to the newly formed Association of Breast Surgery (ABS), also a company limited by guarantee (Company No. 7207053, Registered Charity No. 1135699). From that point, the two Associations became legally independent entities, while entering into a service agreement to support any shared administrative functions.

Over time, the degree of operational separation has increased to allow each Association to develop its own identity and strategic direction, while maintaining a collaborative relationship on matters of shared interest.

**BASO - THE ASSOCIATION FOR CANCER SURGERY  
COMPANY LIMITED BY GUARANTEE  
TRUSTEES' ANNUAL REPORT (continued)**

**YEAR ENDED 30 JUNE 2025**

---

In May 2020, both Associations completed the separation of their joint database and IT systems, while agreeing to retain historical records of joint members and records of cross-attendance (ABS members attending BASO events and vice versa). The service agreement remains in place and is periodically reviewed to ensure its continued relevance and fairness to both parties.

At present, no further significant structural changes are anticipated, and both Associations continue to work cooperatively while pursuing their individual missions.

**Governance and Management**

Ordinary Members of the BASO~ACS Council and the Honorary Officer position of Vice President (all of whom also serve as Trustees and Directors) are elected through a ballot of the Association's Membership, following a formal call for nominations.

Officer posts are similarly announced through a call for nominations. If more than one nomination is received for a post (excluding the Vice President role), a ballot is held among the Trustees.

All Honorary Officers also serve as Trustees and Directors. All appointments are subsequently ratified by the Membership at the AGM.

The BASO~ACS Council holds National Committee meetings four times a year, where the key business of the Association is considered and agreed. Between meetings, decisions are made via telephone or email communication between the Honorary Officers, while day-to-day operational matters are managed by the Association Manager in consultation with the Honorary Officers.

The Trustees/Directors regularly review the principal risks facing the charity and its reserves policy. This process is supported by an annual internal audit of controls over key financial systems, ensuring the charity maintains sufficient resources to respond to adverse conditions. No major risks were identified by the Trustees during the year.

In determining the activities of the charity, the Trustees have regard to the Charity Commission's guidance on public benefit.

**PLANS FOR THE FUTURE**

Expanding the core membership and increasing the range of specialisms represented remain key objectives for 2024–25. While overall growth in membership has been steady rather than increasing, numbers have remained stable, reflecting strong engagement and retention. The Trustees are actively strengthening relationships with other Associations, fostering improved communication and collaboration in areas of shared interest. The current Trustees themselves represent a wide array of specialisms, bringing valuable experience and diverse perspectives to the Association's governance.

Plans are underway to support smaller, complex cancer surgical groups by offering BASO affiliation and endorsement of their meetings. This initiative will further establish BASO as the umbrella Society for all cancer surgeons, enhancing its role and influence across the specialty.

BASO continues to make significant contributions to national consultations, including those organized by NICE. Trustees are actively building collaborations with Royal Colleges, Cancer Commissioning Boards, Public Health England, the GMC, and other stakeholders, with the aim of sharing knowledge, stimulating debate, and promoting best practice to improve outcomes for cancer patients.

**BASO - THE ASSOCIATION FOR CANCER SURGERY  
COMPANY LIMITED BY GUARANTEE  
TRUSTEES' ANNUAL REPORT (continued)**

**YEAR ENDED 30 JUNE 2025**

---

Research remains a key focus, with BASO funding research grants in partnership with the Rosetrees Trust to support surgical oncology studies. This initiative broadens the scope of research in surgical oncology, with shortlisted projects eligible for inclusion in the NIHR portfolio.

BASO also continues to sponsor and support regional meetings and Student Surgical Societies, fostering engagement and professional development across all levels of surgical education. Trainee membership has been extended to Medical Students and Foundation Year Trainees with an interest in surgical oncology, providing structured support for education, training, and career progression.

As healthcare evolves and training pressures increase, BASO Trainees are focused on enhancing the training experience and professional competence of surgical trainees in oncology, particularly within academic and research domains.

This report has been prepared having taken advantage of the small companies exemption in the Companies Act 2006.

Approved by the Trustees on 10 Nov 2025 and signed on their behalf by:

*Abigail Tomlins*

**Miss Abigail Tomlins  
Honorary Treasurer**

**BASO - THE ASSOCIATION FOR CANCER SURGERY  
COMPANY LIMITED BY GUARANTEE  
INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES  
YEAR ENDED 30 JUNE 2025**

---

I report to the charity trustees on my examination of the accounts of the company for the year ended 30 June 2025 which are set out on pages 13 to 20.

**Responsibilities and basis of report**

As the charity trustees of the company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your company's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

**Independent examiner's statement**

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

*Alex Stone*  
.....  
**Alex Stone FCCA**

Edmund Carr LLP  
146 New London Road  
Chelmsford  
CM2 0AW

*19 January 2026*

**BASO - THE ASSOCIATION FOR CANCER SURGERY  
COMPANY LIMITED BY GUARANTEE**

**STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND  
EXPENDITURE ACCOUNT)**

**YEAR ENDED 30 JUNE 2025**

		Unrestricted Funds	Restricted Funds	Total Funds 2025	Total Funds 2024
	Note	£	£	£	£
<b>INCOME from:</b>					
Donations - Rosetrees Trust		-	25,000	25,000	25,000
Charitable activities:					
Members' subscriptions		33,765	-	33,765	34,726
BASO Conference and Meetings	2	27,508	-	27,508	33,780
Publications - EJSO		124,747	-	124,747	120,040
Investments	3	2,102	1,532	3,634	4,507
<b>TOTAL INCOME</b>		<b>188,122</b>	<b>26,532</b>	<b>214,654</b>	<b>218,053</b>
<b>EXPENDITURE on:</b>					
Charitable activities					
Subscriptions - ESSO		9,295	-	9,295	9,773
BASO Conference and Meetings	2	59,995	-	59,995	51,038
Publications - EJSO		11,235	-	11,235	9,828
Fellowships & awards	4	28,583	29,000	57,583	50,918
Other expenditure	5	109,387	-	109,387	99,464
<b>TOTAL EXPENDITURE</b>		<b>218,495</b>	<b>29,000</b>	<b>247,495</b>	<b>221,021</b>
<b>NET INCOME/(EXPENDITURE)</b>		(30,373)	(2,468)	(32,841)	(2,968)
Transfers between funds		-	-	-	-
<b>NET MOVEMENT IN FUNDS</b>		<b>(30,373)</b>	<b>(2,468)</b>	<b>(32,841)</b>	<b>(2,968)</b>
<b>RECONCILIATION OF FUNDS</b>					
Total funds brought forward		249,186	28,604	277,790	280,758
Total funds carried forward		<b>218,813</b>	<b>26,136</b>	<b>244,949</b>	<b>277,790</b>

The charity has no recognised gains or losses other than the results for the period as set out above.

**The notes on pages 15 to 20 form part of these financial statements.**

**BASO - THE ASSOCIATION FOR CANCER SURGERY  
COMPANY LIMITED BY GUARANTEE**  
**BALANCE SHEET**  
**AS AT 30 JUNE 2025**

		<b>2025</b>	<b>2024</b>
	<b>Note</b>	<b>£</b>	<b>£</b>
<b>FIXED ASSETS</b>			
Tangible assets	<b>10</b>	218	292
<b>CURRENT ASSETS</b>			
Debtors	<b>11</b>	45,722	43,986
Cash at bank		<u>318,080</u>	<u>335,855</u>
		<u>363,802</u>	<u>379,841</u>
<b>CREDITORS: Amounts falling due within one year</b>	<b>12</b>	<u>(119,071)</u>	<u>(102,343)</u>
<b>NET CURRENT ASSETS</b>		244,731	277,498
<b>TOTAL ASSETS LESS CURRENT LIABILITIES/ NET ASSETS</b>		<u><u>244,949</u></u>	<u><u>277,790</u></u>
<b>FUNDS</b>			
Unrestricted	<b>13</b>	218,813	249,186
Restricted	<b>14</b>	26,136	28,604
<b>TOTAL FUNDS</b>		<u><u>244,949</u></u>	<u><u>277,790</u></u>

For the year ending 30 June 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006 and with the Financial Reporting Standard (FRS102) (effective 1 January 2019).

These financial statements were approved by the Trustees on...10 Nov 2025... and are signed on their behalf by:

.....  
*Michael Douek*

**PROFESSOR MICHAEL DOUEK**

Company Registration Number: 7225131

.....  
*Abigail Tomlins*

**MISS ABIGAIL TOMLINS**

**The notes on pages 15 to 20 form part of these financial statements.**

**BASO - THE ASSOCIATION FOR CANCER SURGERY  
COMPANY LIMITED BY GUARANTEE**

**NOTES TO THE FINANCIAL STATEMENTS**

**YEAR ENDED 30 JUNE 2025**

---

**1. ACCOUNTING POLICIES**

**Basis of accounting**

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

BASO - The Association for Cancer Surgery meets the definition of a public benefit entity under FRS102. Assets and Liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes. The financial statements are prepared in sterling, which is the functional currency of the charity, and rounded to the nearest £. The charity is a company limited by guarantee.

**Going Concern**

The financial statements have been prepared on a going concern basis as the Trustees believe that no material uncertainties exist. The Trustees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. The budgeted income and expenditure is sufficient with the level of reserves for the charity to be able to continue as a going concern.

**Incoming Resources**

Income from conferences held during the year is accounted for on an accruals basis. Membership subscriptions are recognised on receipt.

**Resources Expended**

All expenditure is accounted for on an accruals basis and includes VAT as the charity is not VAT registered. The majority of costs are attributable to specific charitable activities (ie conferences/awards). Fellowships and awards are accounted for in the period in which they are notified to the recipient. Governance costs are associated with the governance arrangements of the charity.

**Debtors and creditors**

Trade and other debtors are recognised at the settlement amount due. Creditors are recognised at their settlement amount.

**Cash and cash equivalents**

Cash and cash equivalents comprise cash on hand and deposits.

**Fixed Assets and Depreciation**

Fixed assets are shown at historical cost. Expenditure on tangible fixed assets is capitalised. The cost of other items is written off as incurred.

Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful economic life of that asset as follows:

Computer equipment	25% reducing balance
Fixtures & fittings	25% reducing balance

**BASO - THE ASSOCIATION FOR CANCER SURGERY  
COMPANY LIMITED BY GUARANTEE  
NOTES TO THE FINANCIAL STATEMENTS  
YEAR ENDED 30 JUNE 2025**

---

**ACCOUNTING POLICIES continued**

**Fund accounting**

Funds held by the charity are either:

Unrestricted general funds – these are funds which can be used in accordance with the charitable objects at the discretion of the trustees.

Restricted funds – these are funds that can only be used for particular restricted purposes within the objects of the charity.

**2. CHARITABLE ACTIVITIES**

**SCIENTIFIC CONFERENCE AND MEETINGS**

	<b>Unrestricted Funds</b>	<b>Restricted Funds</b>	<b>Total Funds 2025</b>	<b>Total Funds 2024</b>
<b>Income</b>	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
BASO Conference Fees	22,428	-	22,428	31,780
Lecture grants	4,500	-	4,500	2,000
Other meetings	580	-	580	-
	<b>27,508</b>	<b>-</b>	<b>27,508</b>	<b>33,780</b>
<b>Expenditure</b>				
BASO Conference	59,972	-	59,972	50,899
Other meetings	23	-	23	139
	<b>59,995</b>	<b>-</b>	<b>59,995</b>	<b>51,038</b>

**3. INVESTMENT INCOME**

All of the charity's investment income arises from interest bearing deposit accounts.

**4. FELLOWSHIPS & AWARDS**

	<b>Unrestricted Funds</b>	<b>Restricted Funds</b>	<b>Total Funds 2025</b>	<b>Total Funds 2024</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
Ronald Raven Prize	-	600	600	600
Ronald Raven Travel Scholarships	-	3,000	3,000	-
Alan Edwards Memorial Fund	-	400	400	400
BASO/Rosetrees Research Grant	25,000	25,000	50,000	50,000
Other awards and medals	3,583	-	3,583	1,418
Unclaimed awards released	-	-	-	(1,500)
	<b>28,583</b>	<b>29,000</b>	<b>57,583</b>	<b>50,918</b>
<b>2024</b>	<b>26,418</b>	<b>24,500</b>	<b>50,918</b>	

**BASO - THE ASSOCIATION FOR CANCER SURGERY  
COMPANY LIMITED BY GUARANTEE**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 30 JUNE 2025**

---

**5. OTHER EXPENDITURE**

	Unrestricted Funds	Restricted Funds	Total Funds 2025	Total Funds 2024
	£	£	£	£
Clinical trial sponsorship platform	5,757	-	5,757	-
Staff salaries and pension costs	63,106	-	63,106	55,390
National committee costs	6,092	-	6,092	12,784
Website and IT costs	16,523	-	16,523	10,988
Rent, insurance and sundry expenses	11,016	-	11,016	8,054
Governance costs (note 6)	6,893	-	6,893	12,248
	<u>109,387</u>	<u>-</u>	<u>109,387</u>	<u>99,464</u>
2024	99,464	-	99,464	

**6. GOVERNANCE COSTS**

	Unrestricted Funds	Restricted Funds	Total Funds 2025	Total Funds 2024
	£	£	£	£
Accounting and payroll services	4,503	-	4,503	4,441
Independent examination fee	675	-	675	650
Fees payable to independent examiner	5,178	-	5,178	5,091
Bank charges	549	-	549	510
Legal and professional fees	1,166	-	1,166	6,647
	<u>6,893</u>	<u>-</u>	<u>6,893</u>	<u>12,248</u>

**7. STAFF COSTS AND EMOLUMENTS**

Total staff costs were as follows:	2025	2024
	£	£
Wages & salaries	58,371	49,500
Pension costs (defined contribution scheme)	4,735	5,890
	<u>63,106</u>	<u>55,390</u>

*Particulars of employees:*

The average number of employees during the year was 1, (full-time equivalent - 0.8)  
(2024 - 1 employee and 0.8 FTE)

**BASO - THE ASSOCIATION FOR CANCER SURGERY  
COMPANY LIMITED BY GUARANTEE  
NOTES TO THE FINANCIAL STATEMENTS  
YEAR ENDED 30 JUNE 2025**

---

**8. NET OUTGOING RESOURCES FOR THE YEAR**

	<b>2025</b>	<b>2024</b>
	£	£
This is stated after charging:		
Depreciation	74	177

**9. TRUSTEES' REMUNERATION**

None of the Trustees were paid any remuneration by the Association during the period. Trustees are reimbursed reasonable expenses incurred when acting on behalf of the company. Expenses totalling £1,225 were reimbursed to 8 trustees during the period (2024 - £4,895 to 11 Trustees).

**10. TANGIBLE FIXED ASSETS**

	Computer equipment	Fixtures & fittings	Total
	£	£	£
<b>COST</b>			
At 1 July 2024	2,691	611	3,302
Additions	-	-	-
Disposals	-	-	-
<b>At 30 June 2025</b>	<b>2,691</b>	<b>611</b>	<b>3,302</b>
<b>DEPRECIATION</b>			
At 1 July 2024	2,399	611	3,010
Charge for the year	74	-	74
Disposals	-	-	-
<b>At 30 June 2025</b>	<b>2,473</b>	<b>611</b>	<b>3,084</b>
<b>NET BOOK VALUE</b>			
<b>At 30 June 2025</b>	<b>218</b>	<b>-</b>	<b>218</b>
At 30 June 2024	292	-	292

**11. DEBTORS**

	<b>2025</b>	<b>2024</b>
	£	£
Trade debtors	-	410
Prepayments and accrued income	26,986	24,656
Other Debtors	18,736	18,920
	<b>45,722</b>	<b>43,986</b>

**BASO - THE ASSOCIATION FOR CANCER SURGERY  
COMPANY LIMITED BY GUARANTEE  
NOTES TO THE FINANCIAL STATEMENTS**

**YEAR ENDED 30 JUNE 2025**

---

**12. CREDITORS: Amounts falling due within one year**

	2025	2024
	£	£
Trade creditors	12,878	2,301
Grants payable	38,621	30,000
Accruals	7,624	8,650
Deferred income	59,948	61,392
	<hr/> <u>119,071</u>	<hr/> <u>102,343</u>

Deferred income relates to EJSO royalties received in advance for the following period.

**13. UNRESTRICTED FUNDS**

Current year	Movement in resources:					Balance at 30/06/2025 £	
	Balance at 01/07/2024		Incoming	Outgoing	Transfers		
	£	£	£	£	£		
General unrestricted funds	249,186	<u>188,122</u>	<u>(218,495)</u>	-	-	<u>218,813</u>	
Prior year						Balance at 30/06/2024 £	
	Balance at 01/07/2022		Incoming	Outgoing	Transfers	Balance at 30/06/2024 £	
General unrestricted funds	254,485	<u>191,222</u>	<u>(196,521)</u>	-	-	<u>249,186</u>	-

**14. RESTRICTED FUNDS**

Current year	Movement in resources:					Balance at 30/06/2025 £
	Balance at 01/07/2024		Incoming	Outgoing	Transfers	
	£	£	£	£	£	
a) Alan Edwards Memorial Fund	4,904	265	(400)	-	-	4,769
b) Ronald Raven Prize Fund	1,237	188	(600)	-	-	825
c) Ronald Raven Travelling Fund	22,463	1,079	(3,000)	-	-	20,542
d) BASO/Rosetrees Fund	-	25,000	(25,000)	-	-	-
	<hr/> <u>28,604</u>	<hr/> <u>26,532</u>	<hr/> <u>(29,000)</u>	-	-	<hr/> <u>26,136</u>

a)-c) Prize funds awarded annually

d) Donations from the Rosetrees Trust towards the joint BASO/Rosetrees Research grants.

**BASO - THE ASSOCIATION FOR CANCER SURGERY  
COMPANY LIMITED BY GUARANTEE  
NOTES TO THE FINANCIAL STATEMENTS  
YEAR ENDED 30 JUNE 2025**

---

**14. RESTRICTED FUNDS**

<i>Prior year</i>	<i>Movement in resources:</i>				<i>Balance at 30/06/2024</i>
	<i>Balance at 01/07/2023</i>	<i>Incoming</i>	<i>Outgoing</i>	<i>Transfers</i>	
	<i>£</i>	<i>£</i>	<i>£</i>	<i>£</i>	
a) <i>Alan Edwards Memorial Fund</i>	4,931	373	(400)	-	4,904
b) <i>Ronald Raven Prize Fund</i>	1,567	270	(600)	-	1,237
c) <i>Ronald Raven Travelling Fund</i>	19,775	1,188	1,500	-	22,463
d) <i>BASO/Rosetrees Fund</i>	-	25,000	(25,000)	-	-
	<b>26,273</b>	<b>26,831</b>	<b>(24,500)</b>	<b>-</b>	<b>28,604</b>

**15. ANALYSIS OF NET ASSETS (between restricted and unrestricted funds)**

<i>Current year</i>	<i>Tangible fixed assets</i>	<i>Other net assets</i>	<i>Total</i>
	<i>£</i>	<i>£</i>	<i>£</i>
Restricted funds	-	26,136	26,136
Unrestricted funds	218	218,595	218,813
	<b>218</b>	<b>244,731</b>	<b>244,949</b>
<i>Prior year</i>	<i>Tangible fixed assets</i>	<i>Other net assets</i>	<i>Total</i>
	<i>£</i>	<i>£</i>	<i>£</i>
<i>Restricted funds</i>	-	28,604	28,604
<i>Unrestricted funds</i>	292	248,894	249,186
	<b>292</b>	<b>277,498</b>	<b>277,790</b>

**16. COMPANY LIMITED BY GUARANTEE**

The company is controlled by its members. Every member of the company undertakes to contribute to the assets of the Company in the event of the same being wound up during the time he/she is a member, or within one year afterwards, for the payments of the debts and liabilities of the company contracted before the time at which he/she ceases to be a member and of the costs, charges and expenses of winding up the same, and for the adjustments of the rights of the contributors among themselves such amount as may be required not exceeding one pound.

**17. RELATED PARTY TRANSACTIONS**

There were no related party transactions that require disclosure during the year other than the reimbursement of expenses to Trustees, disclosed in Note 9.